Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) EBITDA Margin (2016 - 2025)

Iradimed (IRMD) has disclosed EBITDA Margin for 13 consecutive years, with 32.23% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 64.0% to 32.23% in Q3 2025 year-over-year; TTM through Sep 2025 was 30.87%, a 96.0% increase, with the full-year FY2024 number at 29.99%, down 57.0% from a year prior.
  • EBITDA Margin was 32.23% for Q3 2025 at Iradimed, down from 33.26% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 35.78% in Q3 2023 to a low of 18.8% in Q2 2021.
  • A 5-year average of 28.68% and a median of 29.57% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 6191bps in 2021, then tumbled -419bps in 2024.
  • Iradimed's EBITDA Margin stood at 26.19% in 2021, then increased by 9bps to 28.62% in 2022, then rose by 3bps to 29.57% in 2023, then grew by 1bps to 29.91% in 2024, then rose by 8bps to 32.23% in 2025.
  • Per Business Quant, the three most recent readings for IRMD's EBITDA Margin are 32.23% (Q3 2025), 33.26% (Q2 2025), and 27.84% (Q1 2025).